Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the cardiac amyloidosis market size evolved in recent years?

In the recent past, there has been robust growth in the market size of cardiac amyloidosis. It is projected to inflate from $5.26 billion in 2024 to $5.75 billion in 2025, displaying a significant compound annual growth rate (CAGR) of 9.2%. Factors attributing to this growth during the historic period include the increasing incidence of conditions related to amyloidosis, a surge in the instances of genetic mutations, amplified awareness, a rise in the number of cases related to transthyretin amyloidosis, and an increasing aging population.

What are the predictions for the cardiac amyloidosis market size in the coming years?

The future is looking bright for the cardiac amyloidosis market as it is predicted to experience robust expansion in the coming several years. By 2029, the market is forecasted to reach a tough value of $8.10 billion, propelled by a compound annual growth rate (CAGR) of 9.0%. The anticipated growth during this period is largely due to factors such as an increase in diagnosis rates, support and initiatives from the government, rising instances of genetic mutations, and patient assistance programs. Some of the notable trends during this forecast period include the emergence of new treatments like vulrisiran, the continued research in gene therapy, cutting-edge advancements in diagnostic technologies, the movement towards precision medicine, and the creation of innovative therapies.

Get your cardiac amyloidosis market report here!

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

What key factors are fueling the growth of the cardiac amyloidosis market?

The growth of the cardiac amyloidosis market is anticipated to be driven by the expanding elderly population. The term elderly population refers to individuals aged 65 or older who may need special health care and aid due to age-associated alterations. The rise in the elderly population can be attributed to increasing life expectancy, progress in healthcare, and decreasing birth rates. This upsurge in the elderly population heightens the occurrence of cardiac amyloidosis, as age is a significant risk element for amyloid protein buildup in the heart. For instance, the Population Reference Bureau, a nonprofit organization based in the US, estimated in January 2024, that the US population aged 65 and over is predicted to expand from 58 million in 2022 to 82 million by 2050, reflecting a 47% growth. Consequently, the burgeoning elderly population will boost the cardiac amyloidosis market.

How is the global cardiac amyloidosis market divided into key segments?

The cardiac amyloidosis market covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis

2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy

3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics

Subsegments:

1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

Who are the key firms paving the way for growth in the cardiac amyloidosis market?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.

What emerging trends are influencing the growth of the cardiac amyloidosis market?

Key players in the cardiac amyloidosis market are devoting their efforts to technological advancements, including AI-based software-only diagnostic devices, with the aim of improving early detection and patient clinical results for this frequently overlooked condition. This diagnostic tool is a software-based medical device that utilizes artificial intelligence to examine echocardiographic imagery and recognize disease symptoms, without relying on additional hardware or comprehensive clinical data. As an example, in November 2024, UK health technology firm Ultromics Ltd. received FDA approval for EchoGo Amyloidosis, a tool powered by AI specifically for the early detection of cardiac amyloidosis. It’s the first device to be granted marketing authorization by the FDA’s Total Product Lifecycle Advisory Program (TAP). EchoGo Amyloidosis employs AI to analyze echocardiograms to identify the disease from a single clip, cater to the pressing need for an earlier diagnosis before it advances undetected.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128

What regions are contributing significantly to the growth of the cardiac amyloidosis market?

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Aminoglycosides Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aminoglycosides-global-market-report

Glycomics or Glycobiology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycomics-or-glycobiology-global-market-report

Smart Insulin Pens Global Market Report 2025

https://thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: